MEDCu Technologies

MEDCu Technologies Overview

MEDCu Technologies is a biotech company focused on developing a cost-effective antimicrobial wound dressing that incorporates copper microparticles. The dressing is designed to provide a barrier against bacterial contamination while concurrently supporting the healing process. The MedCu Wound Dressing contains an internal absorbent layer and one or two nonwoven external layers, all of which are impregnated with copper particles. The dressings are nonirritating and nonsensitizing and are available in three configurations, with or without an adhesive contour. MEDCus products are ideal for acute, diabetic, and chronic wounds. The companys utilization of copper particles has been developed through more than 15 years of intensive research and is protected by more than 30 patents worldwide.

Latest News

Oct 31, 2021 · www.jpost.com

growth-positive

Innovative Israeli 'copper' dressing helps cure diabetic wounds

Israeli company MedCu Technologies has developed a wound dressing containing copper oxide that has been found to significantly stimulate the healing of diabetic wounds. The dressing has received clearance from major international regulatory bodies, including the FDA, for use in acute and chronic wounds. The copper oxide in the dressing has antimicrobial properties and helps protect the wound from infections. It also plays a role in the production of new blood capillaries, which is essential for wound healing. A small clinical trial involving 13 diabetic patients showed an average reduction of 65% in wound size after treatment with the MedCu wound dressing. The company plans to conduct a larger, randomized study to further demonstrate the efficacy of their dressings.

Customers

Nov 23, 2018 · fda.report

growth-positive

Medcu Antibacterial Wound Dressings With Copper-oxide (medcu Abwds) 510(k) FDA Premarket Notification K180643 MedCu Technologies, Ltd.

The article discusses the classification of MedCu Antibacterial Wound Dressings With Copper-Oxide (MedCu ABWDs) by the FDA. The device, developed by MedCu Technologies, Ltd., has been deemed substantially equivalent (SESE) by the FDA. This classification is growth-positive for the company. The key theme of the article is the regulatory approval of the MedCu ABWDs. The key issues discussed in the article are related to customers, as the FDA classification allows the company to market and sell the wound dressings. The article does not mention any specific partners or customers. The date of the event described in the article is November 23, 2018. The confidence level of the answer is 8.

Customers

Funding

Team Members

4

Employees: 11-50

Web & Social Links

Locations

Galgalei ha-Plada St 11, Herzliya, Israel

Photos & Videos

1 item(s)

MEDCu Technologies Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info